Oral l-arginine improves endothelial dysfunction in patients with essential hypertension
- 作者：Lekakis ; John P. ; Papathanassiou ; Sotirios ; Papaioannou ; Theodoros G. ; Papamichael ; Christos M. ; et. al.
- 关键词：l-Arginine ; Endothelium-dependent vasodilation ; Hypertension
- 刊名：International Journal of Cardiology
- 出版年：2002
- 期刊代码：128_01675273
- 类别：med
- 出版时间：December, 2002
- 卷：86
- 期：2-3
- 页码：317-323
- 文件大小：152 K
摘要
Background: l-Arginine is a nitric oxide precursor, which augments endothelium-dependent vasodilatation in hypercholesterolemic humans and animals. Endothelium-dependent vasodilation is attenuated in patients with hypertension; however the effects of oral l-arginine on endothelial function of the conduit arteries in patients with essential hypertension have not previously been investigated. Methods: In a prospective randomized double blind trial, 35 patients with essential hypertension received either 6 g l-arginine (18 subjects) or placebo (17 subjects). Patients were examined for flow-mediated endothelium-dependent dilatation of the brachial artery before and 1.5 h after administration of l-arginine or placebo. At the end of the protocol the nitrate-induced, endothelium-independent vasodilatation was evaluated. Results: Two groups of l-arginine and placebo were similar regarding age, sex, blood lipids, smoking, diabetes, coronary artery disease, body mass index, intima-media thickness of the common carotid artery, clinics blood pressure and baseline brachial artery parameters. Administration of l-arginine or placebo did not change significantly heart rate, blood pressure, baseline diameter, blood flow or reactive hyperemia. l-Arginine resulted in a significant improvement of flow-mediated dilatation (1.7±3.4 vs. 5.9±5.4%, P